| Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes PV Nuzzo, JE Berchuck, K Korthauer, S Spisak, AH Nassar, S Abou Alaiwi, ... Nature medicine 26 (7), 1041-1043, 2020 | 254 | 2020 |
| Proteomic and genetic approaches identify Syk as an AML target CK Hahn, JE Berchuck, KN Ross, RM Kakoza, K Clauser, AC Schinzel, ... Cancer cell 16 (4), 281-294, 2009 | 189 | 2009 |
| Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ... Nature Communications 12 (1), 1979, 2021 | 129 | 2021 |
| Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... Nature communications 12 (1), 808, 2021 | 124 | 2021 |
| The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer JE Berchuck, F Facchinetti, DF DiToro, I Baiev, U Majeed, S Reyes, ... Annals of Oncology 33 (12), 1269-1283, 2022 | 86 | 2022 |
| Integrative clinical and molecular characterization of translocation renal cell carcinoma Z Bakouny, A Sadagopan, P Ravi, NY Metaferia, J Li, S AbuHammad, ... Cell reports 38 (1), 2022 | 84 | 2022 |
| HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer X Lu, K Fong, G Gritsina, F Wang, SC Baca, LT Brea, JE Berchuck, ... Nature genetics 54 (5), 670-683, 2022 | 75 | 2022 |
| Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors S Abou Alaiwi, AH Nassar, W Xie, Z Bakouny, JE Berchuck, DA Braun, ... Cancer immunology research 8 (8), 1075-1084, 2020 | 69 | 2020 |
| Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma AH Nassar, S Abou Alaiwi, SH AlDubayan, N Moore, KW Mouw, ... Genetics in Medicine 22 (4), 709-718, 2020 | 65 | 2020 |
| Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma K Lasseter, AH Nassar, L Hamieh, JE Berchuck, PV Nuzzo, K Korthauer, ... Genetics in Medicine 22 (8), 1366-1373, 2020 | 64 | 2020 |
| Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer F Taza, AE Holler, W Fu, H Wang, N Adra, C Albany, R Ashkar, HH Cheng, ... JCO Precision Oncology 5, 1200-1220, 2021 | 55 | 2021 |
| Clinical considerations for the management of androgen indifferent prostate cancer JE Berchuck, PV Viscuse, H Beltran, A Aparicio Prostate cancer and prostatic diseases 24 (3), 623-637, 2021 | 51 | 2021 |
| Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis JE Berchuck, SC Baca, HM McClure, K Korthauer, HK Tsai, PV Nuzzo, ... Clinical Cancer Research 28 (5), 928-938, 2022 | 50 | 2022 |
| Association of mental health treatment with outcomes for US veterans diagnosed with non–small cell lung cancer JE Berchuck, CS Meyer, N Zhang, CM Berchuck, NN Trivedi, B Cohen, ... JAMA oncology 6 (7), 1055-1062, 2020 | 50 | 2020 |
| Liquid biopsy epigenomic profiling for cancer subtyping SC Baca, JH Seo, MP Davidsohn, B Fortunato, K Semaan, S Sotudian, ... Nature medicine 29 (11), 2737-2741, 2023 | 49 | 2023 |
| Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials RR McKay, J Berchuck, L Kwak, W Xie, R Silver, GJ Bubley, PK Chang, ... The Journal of urology 205 (6), 1689-1697, 2021 | 44 | 2021 |
| Genetic testing in prostate cancer management: Considerations informing primary care VN Giri, TM Morgan, DS Morris, JE Berchuck, C Hyatt, ME Taplin CA: a cancer journal for clinicians 72 (4), 360-371, 2022 | 42 | 2022 |
| Retinal pigment epithelial cell death by the alternative complement cascade: role of membrane regulatory proteins, calcium, PKC, and oxidative stress P Yang, P Baciu, BCP Kerrigan, M Etheridge, E Sung, BA Toimil, ... Investigative Ophthalmology & Visual Science 55 (5), 3012-3021, 2014 | 42 | 2014 |
| Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes N De Sarkar, RD Patton, AL Doebley, B Hanratty, M Adil, AJ Kreitzman, ... Cancer discovery 13 (3), 632-653, 2023 | 40 | 2023 |
| The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma BA McGregor, GP Sonpavde, L Kwak, MM Regan, X Gao, H Hvidsten, ... Annals of Oncology 35 (1), 91-97, 2024 | 39 | 2024 |
